Oncology & Cancer

Genotyping errors plague CYP2D6 testing for tamoxifen therapy

Clinical recommendations discouraging the use of CYP2D6 gene testing to guide tamoxifen therapy in breast cancer patients are based on studies with flawed methodology and should be reconsidered, according to the results of ...

Oncology & Cancer

Scientists link gene to tamoxifen-resistant breast cancers

After mining the genetic records of thousands of breast cancer patients, researchers from the Johns Hopkins Kimmel Cancer Center have identified a gene whose presence may explain why some breast cancers are resistant to tamoxifen, ...

Oncology & Cancer

Total darkness at night is key to success of breast cancer therapy

Exposure to light at night, which shuts off nighttime production of the hormone melatonin, renders breast cancer completely resistant to tamoxifen, a widely used breast cancer drug, says a new study by Tulane University School ...

Oncology & Cancer

Gene marker may predict breast cancer response to tamoxifen

(HealthDay)—Researchers have identified genes that may help predict whether a patient with estrogen receptor (ER)-positive breast cancer is likely to benefit from tamoxifen therapy, according to a study published in the ...

Oncology & Cancer

Breast cancer drug fights fungal disease

Tamoxifen, a drug currently used to treat breast cancer, also kills a fungus that causes a deadly brain infection in immunocompromised patients. The findings, which could lead to new treatments for a disease that kills more ...

page 6 from 15